NasdaqGS:ROIVBiotechs
Is Brepocitinib’s LPP Trial And Mixed Batoclimab Data Altering The Investment Case For Roivant Sciences (ROIV)?
Roivant Sciences recently reported that Priovant has begun enrolling patients in a seamless Phase 2b/3 trial of brepocitinib for lichen planopilaris and released past topline Phase 3 data from Immunovant’s batoclimab thyroid eye disease studies, which did not meet their primary endpoint but showed consistent safety.
The update underscores Roivant’s growing late-stage immunology pipeline, led by brepocitinib’s FDA Priority Review in dermatomyositis and multiple additional indications...